These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 19020197

  • 1. Strategies for preventing respiratory syncytial virus.
    Forbes M.
    Am J Health Syst Pharm; 2008 Dec 01; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
    [Abstract] [Full Text] [Related]

  • 2. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D, Cummins C, Bayliss S, Sandercock J, Burls A.
    Health Technol Assess; 2008 Dec 01; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [Abstract] [Full Text] [Related]

  • 3. A review of palivizumab and emerging therapies for respiratory syncytial virus.
    Shadman KA, Wald ER.
    Expert Opin Biol Ther; 2011 Nov 01; 11(11):1455-67. PubMed ID: 21831008
    [Abstract] [Full Text] [Related]

  • 4. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
    Groothuis JR, Nishida H.
    Pediatr Int; 2002 Jun 01; 44(3):235-41. PubMed ID: 11982888
    [Abstract] [Full Text] [Related]

  • 5. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
    Teusink-Cross A, Davies SM, Danziger-Isakov L, El-Bietar J, Grimley MS.
    Biol Blood Marrow Transplant; 2016 Oct 01; 22(10):1904-1906. PubMed ID: 27422147
    [Abstract] [Full Text] [Related]

  • 6. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
    Cochrane Database Syst Rev; 2013 Apr 30; (4):CD006602. PubMed ID: 23633336
    [Abstract] [Full Text] [Related]

  • 7. Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab.
    Bauman J, Eggleston M, Oquist N, Malinoski F.
    South Med J; 2007 Jul 30; 100(7):669-76. PubMed ID: 17639745
    [Abstract] [Full Text] [Related]

  • 8. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.
    Robinson RF, Nahata MC.
    Am J Health Syst Pharm; 2000 Feb 01; 57(3):259-64. PubMed ID: 10674778
    [Abstract] [Full Text] [Related]

  • 9. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC.
    Clin Ther; 2004 Dec 01; 26(12):2130-7. PubMed ID: 15823776
    [Abstract] [Full Text] [Related]

  • 10. Current strategies in the prevention of respiratory syncytial virus disease.
    Paes BA.
    Paediatr Respir Rev; 2003 Mar 01; 4(1):21-7. PubMed ID: 12615029
    [Abstract] [Full Text] [Related]

  • 11. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov 01; 102(5):1211-6. PubMed ID: 9794957
    [Abstract] [Full Text] [Related]

  • 12. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    Meissner HC, Long SS, American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec 01; 112(6 Pt 1):1447-52. PubMed ID: 14654628
    [Abstract] [Full Text] [Related]

  • 13. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
    Venkatesh MP, Weisman LE.
    Expert Rev Vaccines; 2006 Apr 01; 5(2):261-8. PubMed ID: 16608425
    [Abstract] [Full Text] [Related]

  • 14. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec 01; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
    Gutfraind A, Galvani AP, Meyers LA.
    JAMA Pediatr; 2015 Apr 01; 169(4):341-8. PubMed ID: 25706618
    [Abstract] [Full Text] [Related]

  • 16. [Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].
    Scholz H.
    Z Geburtshilfe Neonatol; 2000 Apr 01; 204(3):120-2. PubMed ID: 10909169
    [Abstract] [Full Text] [Related]

  • 17. New strategies for control of respiratory syncytial virus infection.
    Nokes JD, Cane PA.
    Curr Opin Infect Dis; 2008 Dec 01; 21(6):639-43. PubMed ID: 18978532
    [Abstract] [Full Text] [Related]

  • 18. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M, Bedford-Russell A, Sharland M.
    Monaldi Arch Chest Dis; 2000 Aug 01; 55(4):333-8. PubMed ID: 11057088
    [Abstract] [Full Text] [Related]

  • 19. Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants.
    Lanari M, Silvestri M, Rossi GA.
    Curr Drug Metab; 2013 Feb 01; 14(2):216-25. PubMed ID: 22935064
    [Abstract] [Full Text] [Related]

  • 20. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 01; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.